Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20427Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Konitsiotis, S. | en |
| dc.contributor.author | Pappa, S. | en |
| dc.contributor.author | Mantas, C. | en |
| dc.contributor.author | Mavreas, V. | en |
| dc.date.accessioned | 2015-11-24T19:07:21Z | - |
| dc.date.available | 2015-11-24T19:07:21Z | - |
| dc.identifier.issn | 0885-3185 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20427 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Akathisia, Drug-Induced/*drug therapy | en |
| dc.subject | Antipsychotic Agents/adverse effects | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Nootropic Agents/*therapeutic use | en |
| dc.subject | Piracetam/*analogs & derivatives/therapeutic use | en |
| dc.subject | Single-Blind Method | en |
| dc.title | Levetiracetam in tardive dyskinesia: an open label study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1002/mds.20835 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16637037 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1002/mds.20835/asset/20835_ftp.pdf?v=1&t=h0cerhj7&s=9d15f8da879a355a67c94193bf0905fffdbe64f5 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia were evaluated in an open label study. Eight patients received oral LEV (1,000 mg/day) for 1 month and blinded evaluations were performed at baseline and at the end of the treatment period. A significant reduction of the abnormal movements was recorded while psychiatric symptoms did not worsen and the adverse event profile was benign. LEV may be efficacious for the treatment of tardive dyskinesia and deserves further clinical testing. | en |
| heal.journalName | Mov Disord | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Konitsiotis-2006-Levetiracetam in tar.pdf | 52.99 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
